T1a 肾癌冷冻消融术--波兰的首次经验。

Polish journal of radiology Pub Date : 2024-09-23 eCollection Date: 2024-01-01 DOI:10.5114/pjr/191839
Grzegorz Rosiak, Jakub Franke, Dariusz Konecki, Krzysztof Milczarek, Tomasz Ostrowski, Robert Nowakowski, Tomasz Demkow, Zbigniew Gałązka
{"title":"T1a 肾癌冷冻消融术--波兰的首次经验。","authors":"Grzegorz Rosiak, Jakub Franke, Dariusz Konecki, Krzysztof Milczarek, Tomasz Ostrowski, Robert Nowakowski, Tomasz Demkow, Zbigniew Gałązka","doi":"10.5114/pjr/191839","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cryoablation is one of the methods of treating patients with renal cancer with curative intent. This procedure is not widely available in Poland due to the lack of reimbursement until April 2023. The purpose of this study is to present the results of the first experiences in cryoablation of renal cell carcinoma in Poland.</p><p><strong>Material and methods: </strong>Patients with renal cell carcinoma in T1a stage (up to 4 cm in diameter) were treated with percutaneous cryoablation between December 2020 and December 2023. All patients were disqualified from surgical treatment due to age, comorbidities, or history of nephrectomy. Diagnosis was confirmed by computed tomography (CT)-guided core needle biopsy that was performed 2-4 weeks before cryoablation.</p><p><strong>Results: </strong>Twenty-five patients underwent CT-guided cryoablation of T1a renal cancer. The mean age of the patients was 77 years (43-91 years). The mean diameter of lesions was 27 mm (15-40 mm). None of the patients presented with local or distant recurrence within the mean 12-months of follow-up period (100% progression-free survival). Urine leak treated with a stent was detected in one patient. Four patients died within the follow-up period, but none of the deaths was directly related to the procedure.</p><p><strong>Conclusions: </strong>Cryoablation is an effective and safe procedure and should be available to more patients in Poland.</p>","PeriodicalId":94174,"journal":{"name":"Polish journal of radiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497588/pdf/","citationCount":"0","resultStr":"{\"title\":\"T1a renal cancer cryoablation - first experiences in Poland.\",\"authors\":\"Grzegorz Rosiak, Jakub Franke, Dariusz Konecki, Krzysztof Milczarek, Tomasz Ostrowski, Robert Nowakowski, Tomasz Demkow, Zbigniew Gałązka\",\"doi\":\"10.5114/pjr/191839\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Cryoablation is one of the methods of treating patients with renal cancer with curative intent. This procedure is not widely available in Poland due to the lack of reimbursement until April 2023. The purpose of this study is to present the results of the first experiences in cryoablation of renal cell carcinoma in Poland.</p><p><strong>Material and methods: </strong>Patients with renal cell carcinoma in T1a stage (up to 4 cm in diameter) were treated with percutaneous cryoablation between December 2020 and December 2023. All patients were disqualified from surgical treatment due to age, comorbidities, or history of nephrectomy. Diagnosis was confirmed by computed tomography (CT)-guided core needle biopsy that was performed 2-4 weeks before cryoablation.</p><p><strong>Results: </strong>Twenty-five patients underwent CT-guided cryoablation of T1a renal cancer. The mean age of the patients was 77 years (43-91 years). The mean diameter of lesions was 27 mm (15-40 mm). None of the patients presented with local or distant recurrence within the mean 12-months of follow-up period (100% progression-free survival). Urine leak treated with a stent was detected in one patient. Four patients died within the follow-up period, but none of the deaths was directly related to the procedure.</p><p><strong>Conclusions: </strong>Cryoablation is an effective and safe procedure and should be available to more patients in Poland.</p>\",\"PeriodicalId\":94174,\"journal\":{\"name\":\"Polish journal of radiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497588/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Polish journal of radiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pjr/191839\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish journal of radiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pjr/191839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:低温消融术是治疗肾癌患者的方法之一,具有治愈的目的。由于在 2023 年 4 月之前无法报销费用,这种手术在波兰尚未普及。本研究的目的是介绍波兰首次冷冻消融治疗肾细胞癌的结果:在 2020 年 12 月至 2023 年 12 月期间,对 T1a 阶段(直径不超过 4 厘米)的肾细胞癌患者进行了经皮冷冻消融治疗。所有患者均因年龄、合并症或肾切除术史而不符合手术治疗条件。诊断由计算机断层扫描(CT)引导的核心针活检证实,活检在冷冻消融术前2-4周进行:25名T1a肾癌患者在CT引导下接受了冷冻消融术。患者的平均年龄为 77 岁(43-91 岁)。病灶的平均直径为 27 毫米(15-40 毫米)。在平均 12 个月的随访期内,没有一名患者出现局部或远处复发(100% 无进展生存率)。一名患者接受了支架治疗后出现尿漏。四名患者在随访期间死亡,但无一例与手术直接相关:低温消融术是一种有效、安全的治疗方法,在波兰应向更多患者推广。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
T1a renal cancer cryoablation - first experiences in Poland.

Purpose: Cryoablation is one of the methods of treating patients with renal cancer with curative intent. This procedure is not widely available in Poland due to the lack of reimbursement until April 2023. The purpose of this study is to present the results of the first experiences in cryoablation of renal cell carcinoma in Poland.

Material and methods: Patients with renal cell carcinoma in T1a stage (up to 4 cm in diameter) were treated with percutaneous cryoablation between December 2020 and December 2023. All patients were disqualified from surgical treatment due to age, comorbidities, or history of nephrectomy. Diagnosis was confirmed by computed tomography (CT)-guided core needle biopsy that was performed 2-4 weeks before cryoablation.

Results: Twenty-five patients underwent CT-guided cryoablation of T1a renal cancer. The mean age of the patients was 77 years (43-91 years). The mean diameter of lesions was 27 mm (15-40 mm). None of the patients presented with local or distant recurrence within the mean 12-months of follow-up period (100% progression-free survival). Urine leak treated with a stent was detected in one patient. Four patients died within the follow-up period, but none of the deaths was directly related to the procedure.

Conclusions: Cryoablation is an effective and safe procedure and should be available to more patients in Poland.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信